Reduction of charge-modified LDL by statin therapy in patients with CHD or CHD risk factors and elevated LDL-C levels: The SPECIAL Study

Modified Forms of LDL in Plasma

“…This limits their use for routine analysis of lipoprotein profiles. However, more reliable techniques for rapid analysis have recently been developed, including capillary electrophoresis and ELISA (Santo Faulin Tdo, 2008;Zhang, 2009;Zhang, 2008). These methods have confirmed previous data obtained by anion-exchange chromatography.…”

Effects of rosuvastatin on electronegative LDL as characterized by capillary isotachophoresis: the ROSARY Study

“…Pitavastatin, another strong statin, has been shown to decrease the secretion of apoB from HepG2 cells ( 36 ) and to reduce VLDL secretion in Watanabe heritable hyperlipidemic rabbits ( 37 ), an animal model of familial hypercholesterolemia. We showed that both the common statins pravastatin and simvastatin ( 23 ), and rosuvastatin ( Table 1 ) effectively reduced RLP-C levels. We consistently found an association between cITP fLDL and RLP-C in patients with HC in our previous studies ( 22,23 ) and in the present study ( Table 3 ).…”

“…Our recent study ( 23 ) showed that cITP fLDL levels were elevated in patients with HC and risk factors of CHD and were effectively reduced by low-dose pravastatin and simvastatin (The SPECIAL study).…”

“…Our previous study ( 23 ) showed that two commonly used statins, pravastatin and simvastatin, effectively reduced cITP fLDL in patients with HC and risk factors of CHD (the SPECIAL study). However, when plasma d>1.006 g/ml fraction (depleted of TRL) and d>1.040 g/ml fraction (contains sdLDL) from a patient with HDL defi ciency were analyzed, we found that a new LDL(-) subfraction that had faster electrophoretic mobility than fLDL, i.e., vfLDL, was drastically increased ( 19 ).…”

Reactivity of Direct Assays for Low-Density Lipoprotein (LDL) Cholesterol Toward Charge-Modified LDL in Hypercholesterolemia

“…19,21,24- 28 Homogeneous assays for LDL-C were performed simultaneously in whole serum and serum d>1.006 g/ml and >1.040 g/ml fractions on an autoanalyzer (Hitachi 7600-020S; Hitachi HighTechnologies, Tokyo, Japan) according to the manufacturer's protocols, as described previously. 21, 26 Reagents for the 2 LDL-C homogeneous assays, that is, the selective elimination method (LDL-C [Se]) and the selective solubilization method (LDL-C [Ky]) were obtained from Sekisui Medical (Tokyo, Japan) and Kyowa Medex (Tokyo, Japan), respectively. The number of LDL and sdLDL particles were measured as apoB concentration in serum d>1.006 g/ml and >1.040 g/ml fractions, respectively.…”